Skip to Content

Elexacaftor / ivacaftor / tezacaftor Disease Interactions

There are 5 disease interactions with elexacaftor / ivacaftor / tezacaftor:

Major

Elexacaftor (applies to elexacaftor/ivacaftor/tezacaftor) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Liver Disease

Elexacaftor (available only in combination with ivacaftor and tezacaftor) should not be used in patients with severe hepatic impairment and its use in patients with moderate hepatic impairment should be limited to those patients for which there is a clear medical need and the benefit exceeds the risks. If elexacaftor is used in patients with moderate hepatic impairment, the dose should be reduced and liver function tests should be closely monitored.

Moderate

Elexacaftor (applies to elexacaftor/ivacaftor/tezacaftor) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Renal Dysfunction

Elexacaftor (available only in combination with ivacaftor and tezacaftor), has not been studied in patients with severe renal impairment or end-stage renal disease. No dosage adjustment is recommended in patients with mild (eGFR 60 to <90 mL/min/1.73 m2) or moderate (eGFR 30 to <60 mL/min/1.73 m2) renal impairment. Use with caution in patients with severe (eGFR <30 mL/min/1.73 m2) renal impairment or end-stage renal disease.

Moderate

Ivacaftor (applies to elexacaftor/ivacaftor/tezacaftor) cataracts

Moderate Potential Hazard, Moderate plausibility.

Cases of non- congenital lens opacities or cataracts have been reported in pediatric patients treated with ivacaftor, and although other risk factors could be present in some cases, a possible risk attributable to this medication cannot be excluded. Baseline and ophthalmological examinations are recommended in pediatric patients initiating treatment. Caution is advised in patients with ophthalmologic conditions.

Moderate

Ivacaftor (applies to elexacaftor/ivacaftor/tezacaftor) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Elevated transaminases have been reported in patients with cystic fibrosis receiving ivacaftor. It is recommended that liver function tests are assessed prior to treatment, every 3 months during the first year, and annually thereafter. Patients with increased levels should be closely monitored until the abnormalities resolve, and dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN). In patients with hepatic impairment, no dose adjustment is necessary in patients with mild impairment, but a reduced dose of ivacaftor is recommended in patients with moderate impairment (see prescribing information for dosing recommendations). Studies have not been conducted in patients with severe hepatic impairment, but exposure is expected to be higher than in patients with moderate impairment. Therefore, caution should be used on these patients, and a reduced dose is recommended after weighing the risks and benefits of treatment.

Moderate

Ivacaftor (applies to elexacaftor/ivacaftor/tezacaftor) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Ivacaftor has not been studied in patients with renal impairment. No dose adjustment is necessary for patients with mild or moderate renal impairment, however, caution is recommended in patients with severe renal impairment or end-stage renal disease.

Elexacaftor / ivacaftor / tezacaftor drug interactions

There are 398 drug interactions with elexacaftor / ivacaftor / tezacaftor

Elexacaftor / ivacaftor / tezacaftor alcohol/food interactions

There is 1 alcohol/food interaction with elexacaftor / ivacaftor / tezacaftor

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.